Sangamo: Informationen zu Partner,

Informationen zu Partner, Ventures und Patentrecht

 

Sangamo hat eine Unzahl von Partner besonders solche von  Universitäten und Kliniken.  In den USA gibt es übrigens kein Verbot   zur Darstellung der Gehälter in der Öffentlichkeit. I.G., die Banker und  Manager von Firmen müssen es sogar publizieren, anders als in  Deutschland.

Informationen über die Partner findet sich unter:

http://www.investorvillage.com/mbthread.asp?mb=1933&tid=10039907&showall=1

Die Liste lässt ahnen, wie sehr die  Zink-Finger-Methode von Sangamo bereits angewandt wird. Und da finden  sich ausschließlich Institute der ersten Adresse, Harvard, Berkeley und  co

 

 

Folgend ein Teil von Sangamos Quartalsbericht. Daraus kann mal ableiten, dass es eventuell ein break evwn gibt, denn voraussichtliche Ausgaben und Einnahmen stehen fast gleich.  Fall noch paar zusätzliche mio reinkommen, kommen schwarze Zahlen. Und dies wird den Kurs beschleunigen

 

Full Year Results

For the year ended December 31, 2010, the consolidated net loss was $24.9 million, or $0.55 per share, compared to a consolidated net loss of $18.6 million, or $0.44 per share, for the year ended December 31, 2009.  Revenues were $20.8 million in 2010, compared to $22.2 million in 2009. Total operating expenses were $45.7 million for 2010 and $41.6 million for 2009.

Financial Guidance and Anticipated Clinical Milestones in 2011

Sangamo expects to have cash, cash equivalents, marketable securities and interest receivable in the range of approximately $35-40 million  at the end of 2011 exclusive of any new funding from partnerships or  other sources.  Sangamo also expects 2011 operating expenses to be  relatively flat compared to 2010 in the range of approximately $43-47 million.

In 2011, the company expects the following clinical data milestones in its two lead programs:  

• Presentation of preliminary data from Phase 1 clinical trials of SB-728-T for HIV/AIDS in Q1 2011.
• Presentation of additional data from its SB-728-T clinical trials in the second half of 2011.
• Announcement  of clinical trial results from Sangamo's double-blind,  placebo-controlled Phase 2b trial (SB-509-901) of SB-509 for the  treatment of moderately severe diabetic neuropathy in the fourth quarter  of 2011.

 

Also eine Phase in der Neuropathologie hinsichtlich diabetisch bedingte Nervenerkrankungen wurde abgeschlossen. Die Ergebnisse der Doppelblindstudien werden aber erst Ende 2011 zugänglich sein.

Und ein klinischer Test in Sachen Anwendung  der Zinkfingermethode für AIDS Infizierte wurde begonnen.

Darüberhinaus wurden Ergebnisse verschiedener Studien publiziert.

 

Recent Highlights from the Fourth Quarter 2010

• Completion of Enrollment of Phase 2b Clinical Trial (SB-509-901) in Moderately Severe Diabetic Neuropathy.  In January 2011,  Sangamo announced the completion of enrollment of its Phase 2b clinical  trial (SB-509-901) of SB-509 in 170 subjects with moderately severe  diabetic neuropathy. Sangamo expects to have data from the double-blind,  placebo-controlled study in the fourth quarter of 2011.
• Initiation  of New Phase 1/2 Clinical Trial (SB-728-T-1002) of its ZFN-based T-cell  Product SB-728 in Treatment Naïve Subjects with HIV.  In October 2010,  Sangamo announced the initiation of a new trial of its SB-728-T product  for HIV/AIDs (SB-728-T-1002) in HIV-infected subjects that are not on  antiretroviral therapy (HAART).  Sangamo also announced the completion  of enrollment of its ongoing Phase 1 clinical trial of SB-728-T  (SB-728-T-902) in HIV-infected subjects that are on HAART as well as the  expansion of this trial to include a cohort of subjects that are  failing HAART.  The expansion of the SB-728-T program means that the  zinc finger protein (ZFP) Therapeutic is being evaluated in the full  spectrum of HIV-infected individuals from those who are newly infected  to subjects who have undergone multiple rounds of HAART.
• Receipt of $978,000 of Qualifying Therapeutic Discovery Project Funding for the Development of Four ZFP Therapeutic® Programs. Sangamo was awarded cash grants of $244,000  for each of its four qualifying therapeutic projects under the  Qualifying Therapeutic Discovery Project Program established by the  Patient Protection and Affordable Care Act.
• Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting.  Data from Sangamo's Phase 2 clinical trial (SB-509-801) of its ZFP  Therapeutic program to develop a treatment for ALS were presented at the  Society for Neuroscience Meeting. The data demonstrated that the drug  was well-tolerated in subjects with ALS and that 40% of SB-509 treated  subjects had delayed deterioration of toe and ankle muscle strength as  measured by manual muscle testing (MMT) compared to 23% of  baseline-matched historic controls.
• Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction via Systemic Delivery at American Society for Hematology Meeting.  Preclinical data were presented that demonstrate the ability to  permanently correct a disease gene in an animal using systemic delivery  of zinc finger nucleases (ZFNs).  ZFN's were used to correct the human  Factor 9 gene which resulted in the production of corrected human Factor  9 protein at levels that restored normal blood clotting times in a  mouse model of hemophilia B.  The presentation was one of four made at  this meeting by Sangamo's collaborators.
• Publication of Data in Journal of Neuroscience From Program to Develop a ZFP Therapeutic® for Parkinson's Disease.  Sangamo scientists and their collaborators published preclinical data  demonstrating protection of nerve tissue and functional improvements in  motor symptoms in a validated rat model of Parkinson's disease (PD)  using Sangamo's ZFP technology.  The studies were funded by MJFF.  The  data are the basis for a further grant from MJFF to advance the program  to the next stage of preclinical development supporting studies in a  non-human primate model of PD, which are ongoing in collaboration with  scientists at UCSF.

 

Hallo leute,
guckt euch dieses papier mal an das kan doch nicht sein ien tag soviel prosent -
US87911F1012  

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).          UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                    OMB APPROVAL OMB Number: 3235-0287 Expires: February 28, 2011 Estimated average burden hours per response... 0.5                        Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940                              1. Name and Address of Reporting Person *   Gregory Philip D 2. Issuer Name and Ticker or Trading Symbol   SANGAMO BIOSCIENCES INC [ SGMO ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)   _____ Director                      _____ 10% Owner __ X __ Officer (give title below)      _____ Other (specify below) CSO & Vice President, Research (Last)          (First)          (Middle)   C/O SANGAMO BIOSCIENCES INC., POINT RICHMOND TECH CNTR, 501 CANAL BLVD 3. Date of Earliest Transaction (MM/DD/YYYY)   2/1/2011 (Street)   RICHMOND, CA 94804 (City)        (State)        (Zip) 4. If Amendment, Date Original Filed (MM/DD/YYYY)     6. Individual or Joint/Group Filing (Check Applicable Line)   _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person         Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock   2/1/2011     S (1)    300   D $7.96   11633   D     Common Stock   2/1/2011     S (1)    1900   D $7.97   9733   D     Common Stock   2/1/2011     S (1)    300   D $7.98   9433   D             Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivate Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares     Explanation of Responses: (   1)  The sales reported in this Form 4 were effected pursuant to a Rule  10b5-1 trading plan adopted by the Reporting Person on March 8, 2010.     Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Gregory Philip D C/O SANGAMO BIOSCIENCES INC. POINT RICHMOND TECH CNTR, 501 CANAL BLVD RICHMOND, CA 94804     CSO & Vice President, Research       Signatures /s/ Philip D. Gregory   2/1/2011

 

Aber nicht mehr lange. Umso länger die Aktie auf dem Kurs zwischen 5.5 und 6 Euro schwebt, umso größers das Auftriebspotential vor den News im März-April

 

Gutten morgen an alle,
bitte gut zu höhren
http://bl156w.blu156.mail.live.com/default.aspx  

 

 

wenn das Ding schon so beworben wird...

 

und bin positiv eingestellt.

jedoch hab ich auch zweifel, weil wie schon mein vorredner ( electromaniac ) schrieb, das *DING so extrem beworben wird ???

warum haben dann nicht schon mehrere investoren ihr geld in sangamo investiert? oder springen alle erst dann hinein, wenn die rakete abhebt?

MFG der Ostharzer 

 

 

abwarten, dan kans ja nur 500 euro felieren  

9379 % aus 500 Euro wird 48.000€  im Jahr 2011 nach vorsichtiger Schätzung...

mann !

ich bin zwar investiert, aber bei so einer werbung fang ich zu zweifeln an...

 

 

 

 

anfangs dachte ich auch menne..... *WOW.... tolle werbung.  jedoch nun so nach einiger zeit zweifel.

aba warten wir eben noch ab. ich glaub, nächste woche geht sangamo an so einer investorenmesse, wenn ich das richtig übersetzt habe. jedoch ist mein englisch nicht so perfekt. *SCHMUNZEL ...

 

Texte, bähh.

 

auf einmal wieder. Gibt es was besonderes?

 

na da geht heut schon etwas.  sind bestimmt *UMSCHICHTUNGEN von der tiscon, weil die soviel zugelegt hat.

 

 

 

die homepage ist hinlänglich bekannt, denke ich. Gevestor übertreibt, damit das Portal Kunden bekommt. Etwas schade für Sangamo, denn die Prospekte erwecken eine zu große Erwartungshaltung. Für viele abschreckend, weil es fast schon an Spam grenzt. Zugebebener maßen bin ich wegen Gevestor auch wieder in die Aktie rein, nachdem ich Jahre zuvor lange investiert war. Aber da ging halt nicht viel. Sangamo  ist jedenfalls, trotz Gevestor, eine Aktie mit extremem Potenzial. Und  deswegen bleibe ich auch wieder für länger drin und lege auch keine stopploss an. In  der Phase ist sie einfach zu volatil.

Ich denke, dass die Aktie noch im Februar die 10 Dollar sehen wird, und mit einer Bandbreite von 12 bis 15 Dollar in den Monaten der Bericherstattungen (April bis Mai) Performieren wird. Und dann gehts steil aufwärts oder auch nicht, je nach Ergebnissen.

 

 

 

 

 

Wahrscheinlich ist die hervorragende Perfomance der Sangamo Aktie am gestrigen Freitag lediglich auf die Ankündigung einer Pressekonferenz zurückzuführen. Aber es geht ja immerhin um updates zur Zinkfingermethode, die ja laut Gevestor der Grund sein soll, weswegen die Aktie bald explodieren sollte.

   

 RICHMOND, Calif., Feb. 7, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq:SGMO - News) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 2:30 pm ET on Monday, February 14, 2011 at the 13th Annual BIO CEO & Investor Conference which will be held in New York City.

 

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

 

Jedenfalls reagierte die Nasdaq entsprechend positive. 11 Prozent, wobei SGMO am 8 Platz rangierte. Siehe w. unten.

 

 

 

On Friday February 11, 2011, 1:18 pm EST

 

NEW YORK (AP) --

A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:  MetroCorp. Bancshares Inc. rose 19.8 percent to $6.69.  Panera Bread Co. rose 16.5 percent to $116.15.  Central BanCorp. rose 14.1 percent to $15.98.  Sharps Compliance rose 13.5 percent to $5.56.  United Stationers Inc. rose 11.5 percent to $69.40.  Knot Inc. (KNOT) rose 11.3 percent to $11.50.  Stamps.com Inc. rose 11.3 percent to $14.20.  Sangamo BioSciences Inc. rose 11.2 percent to $8.54.  JDS Uniphase Corp. rose 9.4 percent to $27.63.  Wright Medical Group Inc. rose 9.1 percent to $16.48.

 

                                                             

Feb 11, 2011 (SmarTrend(R) News Watch via COMTEX) -- Shares of Sangamo  Biosciences (NASDAQ:SGMO) are trading up 8.9% to $8.35 today on above  average volume. Approximately 1.2 million shares have traded hands today  vs. average 30-day volume of 571,000 shares.

Spikes in volume can validate a breakout or signify a  potential turning point. As such, SmarTrend will continue to monitor  shares of SGMO to see if this bullish momentum will continue.

SmarTrend currently has shares of Sangamo Biosciences in an  Uptrend and issued the Uptrend alert on October 14, 2010 at $3.77. The  stock has risen 103.4% since the Uptrend alert was issued.

In the last five trading sessions, the 50-day MA has climbed 3.99% while the 200-day MA has risen 0.63%.

In the past 52 weeks, shares of Sangamo Biosciences have traded  between a low of $2.81 and a high of $8.88 and are now at $8.17, which  is 191% above that low price.

Write to Chip Brian at cbrian@tradethetrend.com